Novo Nordisk Receives First European Approval for Oral Wegovy Pill

Novo Nordisk has obtained the initial European regulatory approval for the oral tablet version of its weight loss drug Wegovy. The approval, announced on July 19, 2026, allows the company to expand the Wegovy franchise with a pill formulation. This marks the first time European regulators have…

First European Approval for Oral Wegovy

Novo Nordisk has received the first European approval for an oral weight loss medication. The approved drug is the pill formulation of Wegovy. This regulatory decision was announced on July 19, 2026. The approval applies to the European market. It allows the oral Wegovy tablet to be marketed in European countries for weight management. This is the first time a European regulatory body has approved an oral form of Wegovy. The approval covers the oral tablet form specifically. No additional details about the approval terms were disclosed in the announcement.

Expansion of the Wegovy Franchise

The approval marks an expansion of the Wegovy franchise. Novo Nordisk now has an oral version of its weight loss drug approved in Europe. This is the first time European regulators have approved this oral formulation. The Wegovy pill adds a new delivery method to the product line. The franchise now includes an oral formulation alongside other forms. The expansion allows the company to offer the drug as a tablet taken by mouth.

Regulatory Milestone Details

The European approval is a significant regulatory milestone for Novo Nordisk. The oral Wegovy pill is intended for weight loss. The company received the approval on July 19, 2026. European health authorities granted marketing authorization for the tablet. The approval covers European markets. The date of July 19, 2026 is when the announcement was made public. This regulatory decision positions the oral Wegovy for commercial distribution in Europe.

Implications for Weight Management

The oral Wegovy pill provides a weight loss treatment option. Patients can take the medication by mouth. This approval gives European patients access to an oral weight loss drug from Novo Nordisk. The company continues to expand its presence in the obesity treatment sector. The first European approval for an oral weight loss drug is a notable achievement. The Wegovy pill offers a new choice for individuals seeking weight management therapy.

Peptides referenced: Semaglutide.